During the last session, Matinas Biopharma Holdings Inc (AMEX:MTNB)’s traded shares were 3.07 million, with the beta value of the company hitting 1.63. At the end of the trading day, the stock’s price was $0.62, reflecting an intraday loss of -67.88% or -$1.31. The 52-week high for the MTNB share is $21.50, that puts it down -3367.74 from that peak though still a striking -206.45% loss since the share price plummeted to a 52-week low of $1.90. The company’s market capitalization is $3.11M, and the average intraday trading volume over the past 10 days was 0.36 million shares, and the average trade volume was 46.54K shares over the past three months.
Matinas Biopharma Holdings Inc (AMEX:MTNB) trade information
Matinas Biopharma Holdings Inc (MTNB) registered a -67.88% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -67.88% in intraday trading to $0.62, hitting a weekly high. The stock’s 5-day price performance is -80.69%, and it has moved by -79.80% in 30 days. Based on these gigs, the overall price performance for the year is -94.07%. The short interest in Matinas Biopharma Holdings Inc (AMEX:MTNB) is 80434.0 shares and it means that shorts have 2.24 day(s) to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 7.12%. While earnings are projected to return 18.18% in 2024.
MTNB Dividends
Matinas Biopharma Holdings Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Matinas Biopharma Holdings Inc (AMEX:MTNB)’s Major holders
Matinas Biopharma Holdings Inc insiders own 2.53% of total outstanding shares while institutional holders control 28.42%, with the float percentage being 29.15%. HIGHBRIDGE CAPITAL MANAGEMENT LLC is the largest shareholder of the company, while 38.0 institutions own stock in it. As of 2024-06-30, the company held over 10.64 million shares (or 4.8971% of all shares), a total value of $1.68 million in shares.
The next largest institutional holding, with 9.32 million shares, is of VANGUARD GROUP INC’s that is approximately 4.2869% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $1.48 million.
